Opaleye Management Inc. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001595855

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q2 2026 · 58 positions · Total reported value $1.10B · Top-10 concentration 64.8% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 50.0% · 13 new · 12 cut · 8 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +40.3% · vs SPY +25.5% · Prev Value $739.73M — last quarter positions weighted by this quarter price moves · ranking

In its Q2 2026 13F filing, Opaleye Management Inc. disclosed 58 equity positions with a combined reported value of $1.10B. The filing implies a focused portfolio: its ten largest positions account for 64.8% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were LQDA ($195.14M), ETON ($103.53M), HROW ($101.93M). By sector, the heaviest allocations are Health Care 90.7%, Materials 1.9%. Versus the prior quarter, allocation shifted toward Health Care (+0.5pp).

Versus the prior quarter, Opaleye Management Inc. opened 13 new positions, trimmed 12 and fully exited 8, a turnover rate of 50.0% of positions. The portfolio's overlap with the prior quarter was 68% of names.

The largest new positions opened in Q2 2026 were IMMX ($24.18M), GLUE ($18.03M), REPL ($15.33M).

Of the 8 positions fully exited versus the prior quarter, the largest were ASRT ($5.06M), STRO ($4.75M), TECX ($3.80M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • IMMX IMMIX BIOPHARMA INC · $24.18M
  • GLUE MONTE ROSA THERAPEUTICS INC · $18.03M
  • REPL REPLIMUNE GROUP INC · $15.33M
  • VSTM VERASTEM INC · $6.88M
  • PHAT PHATHOM PHARMACEUTICALS INC · $2.01M
  • INBX INHIBRX BIOSCIENCES INC · $1.92M
  • COAG HEMAB THERAPEUTICS HOLDINGS · $1.75M
  • TRAX FIRST TRACKS BIOTHERAPEU W/I · $1.31M

Fully Exited (vs previous quarter)

  • ASRT ASSERTIO HOLDINGS INC · prev qtr: $5.06M
  • STRO SUTRO BIOPHARMA INC · prev qtr: $4.75M
  • TECX TECTONIC THERAPEUTIC INC · prev qtr: $3.80M
  • RIGL RIGEL PHARMACEUTICALS INC · prev qtr: $1.89M
  • NXTC NEXTCURE INC · prev qtr: $1.51M
  • CATX PERSPECTIVE THERAPEUTICS INC · prev qtr: $834.00K
  • PLX PROTALIX BIOTHERAPEUTICS INC · prev qtr: $737.80K
  • LBRX LB PHARMACEUTICALS INC · prev qtr: $357.72K

Insider Transactions (Form 4)

Latest Opaleye Management Inc. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-11-05 Buy Grace Therapeutics, Inc. 3,087 $1.77 SEC filing
2026-11-04 Buy Grace Therapeutics, Inc. 5,027 $1.80 SEC filing
2026-11-03 Buy Grace Therapeutics, Inc. 10,328 $1.79 SEC filing
2026-10-26 Buy Grace Therapeutics, Inc. 66,411 $1.77 SEC filing
2026-10-23 Buy Alpha Cognition Inc. 14,973 $8.23 SEC filing
2026-10-22 Buy Alpha Cognition Inc. 17,117 $8.33 SEC filing
2026-10-22 Buy Grace Therapeutics, Inc. 21,390 $1.93 SEC filing
2026-10-19 Buy Grace Therapeutics, Inc. 4,256 $1.88 SEC filing

All insider transactions →

Fund Profile

Opaleye Management Inc. is an SEC-registered 13F filer based in Boston, MA, United States. As of Q2 2026 it reported 58 US equity positions with a combined value of $1.10B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: BOSTON, MA, United States
  • SEC registration: 801-78700 (status: Approved), registered 2013-10-29
  • Regulatory AUM (Form ADV): $802.77M as of 2026-02-19
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 1 private funds, of which 1 hedge funds

Portfolio Structure

  • 58 positions · $1.10B reported value (Q2 2026)
  • Top 10 holdings = 64.8% of reported value
  • Largest position: LQDA (LIQUIDIA CORPORATION) at 17.7%
  • Average position size: $19.04M

Sector Tilt

  • Health Care 90.7%
  • Materials 1.9%
  • Industrials 1.4%
  • (classified holdings cover 94% of value)

Quarterly Activity

  • Q2 2026: 13 new, 14 added, 12 reduced, 8 exited
  • 19 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: The fund appears to maintain a cautious approach with a slight inclination towards growth in the healthcare sector. The addition of new positions in healthcare companies suggests an optimism in the sector's potential, while reductions in some holdings indicate selectivity and risk management. 2. Key Moves: - Added: IRON (DISC MEDICINE INC) with a significant increase of 103.1% in shares, MGTX (MeiraGTx Holdings plc) with a 67.2% increase in shares. - Reduced: LQDA (LIQUIDIA CORPORATION) by 3.8% in shares, HROW (HARROW INC) by 15.3% in shares. - Hold: The majority of the top holdings, including ETON (ETON PHARMACEUTICALS INC COM), URGN (UROGEN PHARMA LTD), APGE (APOGEE THERAPEUTICS INC), SLGL (Sol-Gel Technologies Ltd), RZLT (REZOLUTE INC), and TGTX (TG THERAPEUTICS INC). 3. Portfolio Structure: - Passive/Active: The rebalancing appears more active, with strategic additions and reductions. - Sector Bias: The healthcare sector is the clear bias, with 10 out of 11 top holdings in healthcare. - Risk Appetite: The fund exhibits a moderate risk appetite, with significant additions to high-growth potential companies but also reductions in certain positions. 4. Per-Holding One-Liner: - LQDA (LIQUIDIA CORPORATION): Develops and commercializes innovative therapies for serious diseases. - ETON (ETON PHARMACEUTICALS INC COM): Focuses on the development of treatments for central nervous system disorders. - HROW (HARROW INC): A biopharmaceutical company focused on the development of treatments for cancer. - IRON (DISC MEDICINE INC): Engages in the research and development of therapies for rare and orphan diseases. - URGN (UROGEN PHARMA LTD): Specializes in the development of therapies for urological conditions. - APGE (APOGEE THERAPEUTICS INC): Focuses on the development of therapies for cancer and other diseases. - MGTX (MeiraGTx Holdings plc): Develops treatments for a range of ophthalmic diseases. - SLGL (Sol-Gel Technologies Ltd): Engages in the development and production of advanced materials and technologies. - RZLT (REZOLUTE INC): Specializes in the development of treatments for rare diseases. - TGTX (TG THERAPEUTICS INC): Focuses on the development of therapies for cancer and other diseases. - Unverified: No unverified holdings noted. 5. One-Sentence Style Summary: The fund maintained a selective approach in healthcare, focusing on growth potential with strategic additions and reductions, while maintaining a cautious stance through sector concentration and selective adjustments.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 90.7%
Materials 1.9%
Other 6.0%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 2.45M $195.14M 17.67%
17.67%
Reduce
2 2.86M $103.53M 9.38%
9.38%
Hold
3 2.40M $101.93M 9.23%
9.23%
Reduce
4 855.00K $62.53M 5.66%
5.66%
Add
5 1.44M $52.99M 4.80%
4.80%
Add
6 390.00K $51.76M 4.69%
4.69%
Hold
7 3.55M $47.96M 4.34%
4.34%
Add
8 500.00K $37.07M 3.36%
Form 4 · 2 →
3.36%
Hold
9 6.30M $32.76M 2.97%
2.97%
Hold
10 535.00K $29.39M 2.66%
2.66%
Hold
11 2.35M $24.18M 2.19%
2.19%
New
12 1.32M $23.75M 2.15%
2.15%
Add
13 700.00K $22.90M 2.07%
2.07%
Hold
14 2.90M $20.91M 1.89%
Form 4 · 11 →
1.89%
Add
15 500.00K $20.32M 1.84%
1.84%
Hold
16 100.00K $18.73M 1.70%
1.70%
Hold
17 745.00K $18.03M 1.63%
1.63%
New
18 550.00K $15.48M 1.40%
1.40%
Hold
19 6.79M $15.33M 1.39%
1.39%
Hold
20 1.38M $15.33M 1.39%
1.39%
New
21 338.37K $14.38M 1.30%
1.30%
Add
22 260.00K $14.35M 1.30%
1.30%
Hold
23 122.50K $13.60M 1.23%
1.23%
Hold
24 3.86M $12.51M 1.13%
1.13%
Add
25 100.00K $12.26M 1.11%
1.11%
Hold
26 3.86M $12.02M 1.09%
1.09%
Add
27 931.00K $11.86M 1.07%
1.07%
Reduce
28 1.71M $9.79M 0.89%
0.89%
Reduce
29 1.80M $6.88M 0.62%
0.62%
New
30 1.41M $6.85M 0.62%
0.62%
Hold
31 935.00K $6.47M 0.59%
0.59%
Hold
32 600.00K $5.89M 0.53%
0.53%
Hold
33 310.00K $5.78M 0.52%
0.52%
Reduce
34 700.00K $5.33M 0.48%
0.48%
Add
35 344.02K $4.83M 0.44%
0.44%
Add
36 1.12M $4.62M 0.42%
0.42%
Hold
37 334.44K $4.45M 0.40%
0.40%
Add
38 250.00K $4.23M 0.38%
0.38%
Add
39 1.19M $4.15M 0.38%
0.38%
Add
40 180.00K $4.06M 0.37%
0.37%
Reduce
41 1.00M $3.42M 0.31%
0.31%
Add
42 145.00K $3.22M 0.29%
0.29%
Reduce
43 306.14K $3.06M 0.28%
0.28%
Reduce
44 890.00K $2.72M 0.25%
0.25%
Reduce
45 350.00K $2.48M 0.22%
0.22%
Reduce
46 185.59K $2.01M 0.18%
0.18%
New
47 20.29K $1.92M 0.17%
0.17%
New
48 125.00K $1.82M 0.17%
0.17%
Hold
49 47.65K $1.75M 0.16%
0.16%
New
50 65.00K $1.31M 0.12%
0.12%
New

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q3) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q2)

P 70% R 70% F1 70% (modelled on 2026-Q1; 7/10 hit)

Historical Backtest (10 quarters)

Avg precision 80% · recall 80% · F1 80% · avg rank error 1.9 · Top-10 turnover 20%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 70% 70% 70% HROW · TGTX · SLRN · RYTM · OCUL · CPRX · KROS · ETON · IDYA · ARVN OCUL · HROW · TGTX · KROS · RYTM · CPRX · ARVN · IOVA · JSPR · EWTX
2024-Q2 70% 70% 70% OCUL · HROW · TGTX · KROS · RYTM · CPRX · ARVN · IOVA · APLT · CDXS HROW · TGTX · OCUL · RYTM · KROS · ARVN · IMNM · CYTK · CDXS · EWTX
2024-Q3 80% 80% 80% HROW · TGTX · OCUL · RYTM · KROS · ARVN · IMNM · CDXS · CYTK · EWTX HROW · TGTX · OCUL · ARVN · CDXS · RYTM · KROS · IMNM · LQDA · ETON
2024-Q4 90% 90% 90% HROW · TGTX · OCUL · ARVN · CDXS · RYTM · KROS · LQDA · IMNM · ETON HROW · TGTX · CDXS · ETON · OCUL · ARVN · RYTM · IMNM · LQDA · EWTX
2025-Q1 90% 90% 90% HROW · TGTX · CDXS · ETON · ARVN · OCUL · RYTM · IMNM · LQDA · DNA HROW · ETON · SNWV · LQDA · RYTM · CDXS · IMNM · TGTX · ARVN · OCUL
2025-Q2 100% 100% 100% HROW · ETON · LQDA · SNWV · IMNM · RYTM · CDXS · TGTX · ARVN · OCUL HROW · ETON · IMNM · SNWV · LQDA · CDXS · RYTM · TGTX · OCUL · ARVN
2025-Q3 90% 90% 90% HROW · ETON · IMNM · LQDA · SNWV · CDXS · RYTM · TGTX · OCUL · LRMR HROW · ETON · LQDA · RYTM · IMNM · SNWV · CDXS · TGTX · OCUL · CGON
2025-Q4 70% 70% 70% HROW · LQDA · ETON · RYTM · IMNM · SNWV · CDXS · TGTX · CGON · OCUL HROW · LQDA · ETON · RYTM · APGE · SNWV · STOK · OCUL · SLGL · CGON
2026-Q1 70% 70% 70% HROW · LQDA · ETON · RYTM · APGE · SNWV · STOK · SLGL · OCUL · CGON HROW · LQDA · ETON · SLGL · RYTM · APGE · IRON · URGN · CBIO · STOK
2026-Q2 ★ 70% 70% 70% HROW · LQDA · ETON · SLGL · APGE · RYTM · IRON · URGN · CBIO · STOK LQDA · ETON · HROW · IRON · URGN · APGE · MGTX · SLGL · RZLT · TGTX

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

FAQ

What did Opaleye Management Inc. buy in 2026-Q2?

In its 2026-Q2 13F filing, Opaleye Management Inc. reported 58 equity positions worth $1.10B in aggregate; its largest disclosed positions were LQDA ($195.14M), ETON ($103.53M), HROW ($101.93M).

How large is Opaleye Management Inc.'s portfolio?

Opaleye Management Inc. reported $1.10B of long equity holdings across 58 positions as of 2026-Q2. Top-10 holdings account for 64.8% of reported value.

What is Opaleye Management Inc.'s investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/opaleye-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →